Phase II selective AXL Inhibitor

Pipeline of innovative AXL inhibitors

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients. The company’s proprietary lead candidate, bemcentinib, is a first-in-class, highly selective, potent, and orally bioavailable inhibitor of AXL in a broad phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO)